Interventions for the prevention of mycobacterium avium complex in adults and children with HIV
- 30 April 2013
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2013 (4) , CD007191
Abstract
Mycobacterium avium complex (MAC) infection is a common complication of advanced acquired immunodeficiency syndrome (AIDS) disease and is an independent predictor of mortality and shortened survival. To determine the effectiveness and safety of interventions aimed at preventing MAC infection in adults and children with HIV infection. We searched MEDLINE, EMBASE, and The Cochrane Library (search date December 2012). Randomised controlled trials comparing different strategies for preventing MAC infection in HIV-infected individuals. Two reviewers independently assessed trial eligibility and quality, and extracted data. Where data were incomplete or unclear, a third reviewer resolved conflicts and/or trial authors were contacted for further details. Development of MAC infection and survival were compared using risk ratios (RR) and 95% confidence intervals (CI). The quality of evidence has been assessed using the GRADE methodology. Eight studies met the inclusion criteria. Placebo-controlled trials: There was no statistically significant difference between clofazimine and no treatment groups in the number of patients that developed MAC infection (RR 1.01; 95% CI 0.37 to 2.80). Rifabutin (one study; RR 0.48; 95% CI 0.35 to 0.67), azithromycin (three studies; RR 0.37; 95% CI 0.19 to 0.74) and clarithromycin (one study; RR 0.35; 95% CI 0.21 to 0.58) were more effective than placebo in preventing the development of MAC infection. There was no statistically significant difference between those treated with clofazimine (one study; RR 0.98; 95% CI 0.41 to 2.32), rifabutin (one study RR 0.91; 95% CI 0.78 to 1.05), azithromycin (three studies, pooled RR 0.96; 95% CI 0.69 to 1.32) and placebo in number of reported deaths. One study found that the risk of death was reduced by 22% in patients treated with clarithromycin compared to those treated with placebo (RR 0.78; 95% CI 0.64 to 0.96). Monotherapy vs. monotherapy: Patients treated with clarithromycin (RR 0.60; 95% CI 0.41 to 0.89) and azithromycin (RR 0.60; 95% CI 0.40 to 0.89) were 40% less likely to develop MAC infection than those treated with rifabutin. There was no statistically significant difference between those treated with clarithromycin (RR 0.98; 95% CI 0.83 to 1.15), azithromycin (RR 0.98; 95% CI 0.77 to 1.24) and rifabutin in the number of reported deaths. Combination therapy versus monotherapy: There was no statistically significant difference between patients treated with a combination of rifabutin and clarithromycin and those treated with clarithromycin alone (RR 0.74; 95% CI 0.46 to 1.20); and those treated with combination of rifabutin and azithromycin and those treated with azithromycin alone (RR 0.59; 95% CI 1.03). Patients treated with a combination of rifabutin plus clarithromycin were 56% less likely to develop MAC infection than those treated with rifabutin alone (RR 0.44; 95% CI 0.29 to 0.69). Patients treated with a combination of rifabutin plus azithromycin were 65% less likely to develop MAC infection than those treated with rifabutin alone (RR 0.35; 95% CI 0.21 to 0.59). There was no statistically significant difference in the number of reported deaths in all the four different comparisons of prophylactic agents. Based on limited data, azithromycin or clarithromycin appeared to be a prophylactic agent of choice for MAC infection. Further studies are needed, especially direct comparison of clarithromycin and azithromycin. In additions, studies that will compare different doses and regimens are needed.Keywords
This publication has 36 references indexed in Scilit:
- Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIVAIDS Research and Therapy, 2011
- Clinical, Microbiological, and Immunological Characteristics in HIV-Infected Subjects at Risk for Disseminated Mycobacterium avium Complex Disease: An AACTG StudyAIDS Research and Human Retroviruses, 2005
- A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapyHIV Medicine, 2004
- Prevalence and Clinical Manifestations of DisseminatedMycobacterium aviumComplex Infection in South Africans with Acquired Immunodeficiency SyndromeClinical Infectious Diseases, 2001
- Randomized, Crossover Adherence Trial of Azithromycin and Clarithromycin for Mycobacterium avium Complex Prophylaxis in AIDS PatientsInfectious Diseases in Clinical Practice, 2000
- Successful Short‐Term Suppression of Clarithromycin‐Resistant Mycobacterium avium Complex Bacteremia in AIDSClinical Infectious Diseases, 1999
- Prevention Strategies for Mycobacterium avium-intracellulare Complex (MAC) InfectionDrugs, 1997
- Rationale for the Prevention of Disseminated Mycobacterium avium-intracellulare Complex DiseaseDrugs, 1997
- Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDSNew England Journal of Medicine, 1993
- Incidence of Mycobacterium avium-intracellulare Complex Bacteremia in Human Immunodeficiency Virus-Positive PatientsThe Journal of Infectious Diseases, 1992